Citation Impact
Citing Papers
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
2016
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
2015
The role of JAK/STAT signaling pathway and its inhibitors in diseases
2020
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
2017
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Targeting TRK family proteins in cancer
2017
Macrophages in immunoregulation and therapeutics
2023 Standout
Epigenetic control of gene expression: Potential implications for cancer treatment
2017
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
2017
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia
2013
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
2015
Pacritinib: a new agent for the management of myelofibrosis?
2015
The roles of nucleolin subcellular localization in cancer
2015
Sickle-cell disease
2010 Standout
Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers
2019 Standout
The promise of Janus kinase inhibitors in the treatment of hematological malignancies
2016
<p>GM-CSF: A Promising Target in Inflammation and Autoimmunity</p>
2020
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
2016
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
2020 Standout
The molecular landscape of head and neck cancer
2018 Standout
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
2014
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
2017 StandoutNature
Chronic Myelomonocytic Leukemia
2016
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
2015
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
2018
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a M ayo C linic‐F rench C onsortium S tudy
2014
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
2016
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
1997 Standout
JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age
2015
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
2020
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
2014
Therapy for myeloproliferative neoplasms: when, which agent, and how?
2014
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
2018
Works of Aref Al‐Kali being referenced
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
2013
A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors
2018
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
2013
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
2015
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
2012
Momelotinib therapy for myelofibrosis: a 7-year follow-up
2018
Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience
2014
Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.
2015
SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value
2011
Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment
2015
Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia
2020
Momelotinib treatment‐emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
2014
Therapy-related acute promyelocytic leukemia (t-APL): Observations on APL pathogenesis.
2011
Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies
2015
A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis
2014
Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
2015